PRA Health Sciences (PRAH) Downgraded to Hold at ValuEngine

ValuEngine downgraded shares of PRA Health Sciences (NASDAQ:PRAH) from a buy rating to a hold rating in a research note published on Saturday morning, ValuEngine reports.

Other research analysts have also issued research reports about the company. Robert W. Baird increased their target price on PRA Health Sciences from $119.00 to $122.00 and gave the company an outperform rating in a research report on Thursday, February 28th. Wolfe Research initiated coverage on PRA Health Sciences in a research report on Tuesday, April 2nd. They set a market perform rating on the stock. BidaskClub lowered PRA Health Sciences from a buy rating to a hold rating in a research report on Friday, March 15th. SunTrust Banks increased their target price on PRA Health Sciences to $120.00 and gave the company an average rating in a research report on Monday, March 4th. Finally, Zacks Investment Research lowered PRA Health Sciences from a buy rating to a hold rating in a research report on Wednesday, January 2nd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. PRA Health Sciences presently has a consensus rating of Hold and a consensus price target of $113.22.

Shares of NASDAQ PRAH opened at $101.05 on Friday. The company has a market cap of $6.66 billion, a PE ratio of 25.71, a PEG ratio of 1.50 and a beta of 1.12. PRA Health Sciences has a 12 month low of $79.20 and a 12 month high of $121.98. The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.87 and a current ratio of 0.87.

Several large investors have recently made changes to their positions in PRAH. BlackRock Inc. lifted its holdings in PRA Health Sciences by 1.4% in the 4th quarter. BlackRock Inc. now owns 6,158,867 shares of the medical research company’s stock valued at $566,369,000 after purchasing an additional 84,557 shares in the last quarter. Vanguard Group Inc. lifted its holdings in PRA Health Sciences by 12.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,811,972 shares of the medical research company’s stock valued at $640,421,000 after purchasing an additional 658,191 shares in the last quarter. Vanguard Group Inc lifted its holdings in PRA Health Sciences by 12.8% in the 3rd quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock valued at $640,421,000 after purchasing an additional 658,191 shares in the last quarter. FMR LLC lifted its holdings in PRA Health Sciences by 11.7% in the 4th quarter. FMR LLC now owns 2,588,853 shares of the medical research company’s stock valued at $238,071,000 after purchasing an additional 271,360 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in PRA Health Sciences by 12.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,465,247 shares of the medical research company’s stock valued at $271,645,000 after purchasing an additional 268,243 shares in the last quarter. Hedge funds and other institutional investors own 98.14% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: Is a Roth IRA right for you?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.